文献速递甲状腺疾病

分化型甲状腺癌的TSH切点与复发风险:系统综述与荟萃分析

TSH Cutoffs and Recurrence Risk in Differentiated Thyroid Carcinomas: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究系统检索Ovid-Medline、EMBASE与Cochrane数据库至2024年3月,纳入2项随机对照试验和7项观察性研究共5320例分化型甲状腺癌(DTC)患者,总体复发率为18%。按0.1、0.5、2.0 mIU/L的TSH切点分层,各切点下汇总复发风险均无统计学意义;但剔除显著影响分析的单项研究后,TSH≥0.1 mIU/L复发风险升高(HR 2.27;95%CI 1.29-3.99),伴远处转移者维持TSH≥0.1 mIU/L时复发风险更高(HR 3.3;95%CI 1.53-7.10)。

要点

  • TSH抑制程度与DTC总体复发风险无关
  • 剔除影响性研究后,TSH≥0.1 mIU/L与复发风险升高相关(HR 2.27)
  • 伴远处转移的高危患者维持TSH抑制可能获益

核心结论

  • TSH抑制程度不影响DTC总体复发风险
  • 对伴远处转移的高危患者,TSH抑制可能有助于降低复发风险

研究设计与样本

  • 系统综述与荟萃分析,检索Ovid-Medline、EMBASE和Cochrane数据库至2024年3月
  • 纳入2项随机对照试验和7项观察性研究,共5320例患者

主要发现

  • 总体复发率为18%
  • 按0.1、0.5、2.0 mIU/L各TSH切点分层的汇总复发风险无统计学意义
  • 按ATA复发风险(低危和高危DTC)分层的汇总HR在不同TSH水平间无差异
  • 剔除显著影响分析的研究后,TSH≥0.1 mIU/L者复发风险升高(HR 2.27;95%CI 1.29-3.99)
  • 剔除该研究后,TSH≥2.0 mIU/L者复发风险升高(HR 1.36;95%CI 1.001-1.84)

关键数值与推荐

  • TSH切点分别为0.1、0.5和2.0 mIU/L
  • 伴远处转移者维持TSH≥0.1 mIU/L时复发风险升高(HR 3.3;95%CI 1.53-7.10)

临床怎么用

  • DTC术后TSH抑制目标应结合ATA复发风险个体化制定
  • 远处转移高危患者或可从更严格的TSH抑制中获益
  • 不宜对所有DTC患者统一强化TSH抑制

局限性

  • 部分阳性结果来自剔除影响性研究后的leave-one-out分析
  • 纳入研究以观察性研究为主,仅2项随机对照试验

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The current American Thyroid Association (ATA) guidelines recommend tailored TSH suppression, considering the recurrence risk of differentiated thyroid cancer (DTC); however, the evidence is limited. OBJECTIVE: This meta-analysis aimed to investigate the risk of recurrence in patients with DTC, stratified by the ATA risk of recurrence, according to variable thyrotropin (TSH) cutoffs (0.1, 0.5, and 2.0 mIU/L). METHODS: We searched Ovid-Medline, EMBASE, and Cochrane databases for studies reporting the recurrence rate of DTCs based on TSH cutoffs through March 2024. The search terms used included "thyroid neoplasm" OR "cancer," "TSH" OR "thyroid stimulating hormone," "suppress" OR "supplementation," and "thyroidectomy". RESULTS: Two randomized controlled trials and 7 observational studies, including 5320 patients, were analyzed, with an overall recurrence rate of 18%. The pooled recurrence risk for DTCs at each TSH cutoff (0.1, 0.5, and 2.0 mIU/L) was not significant. In the subgroup analysis, the pooled hazard ratios (HRs) stratified by the ATA risk of recurrence (low- and high-risk DTCs) did not differ according to TSH levels. However, the risks of recurrence increased at serum TSH of 0.1 mIU/L or greater (HR 2.27; 95% CI, 1.29-3.99) and TSH of 2.0 mIU/L or greater (HR 1.36; 95% CI, 1.001-1.84) in a leave-one-out meta-analysis after removing the study that significantly influenced the analysis. Patients with distant metastases had a higher risk of recurrence (HR 3.3; 95% CI, 1.53-7.10) when maintaining a TSH greater than or equal to 0.1 mIU/L. CONCLUSION: The degree of TSH suppression did not affect the overall risk of DTC recurrence. However, TSH suppression may be beneficial in reducing the recurrence risk in high-risk patients with distant metastases.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cho YY, Ahn SH, Kim M, et al. TSH Cutoffs and Recurrence Risk in Differentiated Thyroid Carcinomas: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2025. PMID: 40811629. doi:10.1210/clinem/dgaf463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。